GAS2 and hematologic disorder: Our previous work has shown that the dominant negative form of GAS2 (GAS2DN) exhibits a stronger inhibitory effect on chronic myeloid leukemia (CML) CD34+ cells than on normal CD34+ cells [12]; however, the effect of Gas2 impairment on normal hematopoietic cells has not been studied yet [31], which is critical to determine whether targeting GAS2 is a proper approach to combat hematological malignancies.